|
|
|
 |
|
|
 |
|
|
| |
 |
| |
 |
| |
 |
|
|
Jonathan J. Fleming
- Managing General Partner
Boston, MA
Jonathan Fleming is the Managing General Partner of Oxford Bioscience Partners, an international venture capital firm specializing in life science technology based investments, with offices in Boston and Connecticut.
- more
|
 |
 |
|
|
Douglas M. Fambrough, Ph.D.
- General Partner
Boston, MA
Since joining Oxford in 1999, Dr. Fambrough has specialized in financing innovative life science technology companies.
- more
|
|
 |
|
|
Matthew A. Gibbs
- General Partner
Boston, MA
Mr. Gibbs joined Oxford Bioscience Partners in 1997. He has 15 years of investing experience in the lifescience and technology venture industry.
- more
|
|
 |
|
|
Ellen S. Baron, Ph.D.
- Partner
Boston, MA
Dr. Baron joined Oxford Bioscience Partners in 2003 and is currently is a Partner at the firm. She has over 20 years of operating and investment expertise in the pharmaceutical and biotechnology industry and is focused on all areas of healthcare investing, principally in biotherapeutics.
- more
|
|
 |
|
|
Omar Amirana, M.D.
- Partner
Boston, MA
Dr. Amirana is a Partner at Oxford focused on healthcare technology investing. He joined Oxford in 2005 with 15 years of industry-related experience in both large and small companies.
- more
|
|
 |
|
|
Edmund M. Olivier
- Senior General Partner
Costa Mesa, CA
Mr. Olivier has a profitable record of financing and managing biotechnology and healthcare investments over the last 20 years. He has been Chairman, President or Director of more than twenty life science companies in the U.S., Europe and Asia.
- more
|
|
 |
|
|
Cornelius T. Ryan
- Founding General Partner
Westport, CT
Cornelius T. Ryan (Neil) co-founded Oxford Partners in 1981 and is the only partner involved in all previous Oxford funds. Neil is a Special Limited Founding Partner of Oxford Bioscience III and a General Partner of Oxford Bioscience I and II. - more
|
|
 |
|
|
Alan G. Walton, Ph.D., D.Sc.
- Senior General Partner
Westport, CT
Dr. Walton joined Oxford as a General Partner in 1987. Previously, he was President and CEO of University Genetics Co., a public biotechnology company involved in technology transfer and seed investments in university-related projects.
- more
|
|
| |
|
|
|
|
|
|
|
 |
| |
 |
|
|
David Armistead, Ph.D.
- Executive-in-Residence
Boston, MA
Dr. David Armistead joined Oxford Bioscience Partners as an Executive in Residence in 2004. Prior to joining Oxford, he was Vice President and Site Head for the Amgen Cambridge Research Center where he oversaw all aspects of the East Coast research activities for Amgen Inc. - more
|
|
 |
|
|
Oded Ben-Joseph, Ph.D.
- Executive-in-Residence
Boston, MA
Oded Ben-Joseph, Ph.D., MBA brings significant executive, entrepreneurial and transactional experience to his role as Executive-in-Residence at Oxford Bioscience Partners.
- more
|
|
 |
|
|
Robert Kamen, Ph.D.
- Executive-in-Residence
Boston, MA
Dr. Kamen joined Oxford as an Executive-in-Residence in November 2002. Prior to that, he was president of Abbott Bioresearch Center, Abbott’s immunology/oncology drug discovery and biologics production unit in Worcester, Mass. - more
|
|
 |
|
|
Manuel A. Navia, Ph.D.
- Executive-in-Residence
Boston, MA
Dr. Navia is currently an Executive-in-Residence at Oxford Bioscience Partners. He is also a consultant for a number of pharmaceutical companies in the Boston area.
- more
|
|
 |
|
|
David Poorvin, Ph.D.
- Executive-in-Residence
Boston, MA
Dr. Poorvin has over 35 years of experience in the pharmaceutical and biotech industry.
- more
|
|
 |
|
|
Steven D. Targum, M.D.
- Executive-in-Residence
Boston, MA
Dr. Targum joined Oxford Bioscience Partners in 2005 as an Executive-in-Residence where he advises portfolio companies in CNS drug development.
- more
|
|
 |
|
|
Axel Unterbeck, Ph.D.
- Executive-in-Residence
Boston, MA
Dr. Axel Unterbeck joined Oxford Bioscience Partners in 2005. Prior to joining Oxford, Dr. Unterbeck was President, Chief Scientific Officer, and Co-Founder at Memory Pharmaceuticals, Corp which achieved its initial public offering in April of 2004, NASDAQ: MEMY. - more
|
|
 |
|
|
Lisa Jordan
- Executive-in-Residence
Boston, MA
Ms. Jordan has over 12 years of operating and investment experience in the medical device industry. Prior to Oxford Bioscience Partners, she was a Kauffman Fellow at Spray Venture. - more
|
|
| |
|
|
|
|
|
|
|
|
|
|
|